ADVANCED MEDICAL SOLUTIONS GROUP PLC

Regulatory Filings • Sep 1, 2025

National Storage Mechanism | Additional information

RNS Number : 3098X

Advanced Medical Solutions Grp PLC

01 September 2025

1 September 2025

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Notice of Interim Results

Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS), a world-leading specialist in tissue-healing technologies, will announce its interim results for the six months ended 30 June 2025 on Wednesday 17 September 2025.

A briefing for analysts will be held at 10:45am BST on the day of the results. For further information, please contact [email protected].

At 2:30pm BST the same day, a presentation by Chris Meredith, Chief Executive Officer and Eddie Johnson, Chief Financial Officer will be available via Investor Meet Company.

The presentation is open to all existing and potential shareholders and will also be published on the Company's website following its release.

Investors can sign up to Investor Meet Company for free and add Advanced Medical Solutions plc via: https://www.investormeetcompany.com/advanced-medical-solutions-group-plc/register-investor      

- End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations
Optimum Strategic Communications	Tel: +44 (0) 20 4566 8543
Mary Clark / Nick Bastin / Isabelle Abdou	[email protected]
Investec Bank PLC (NOMAD & Broker)	Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson
Berenberg (Joint Broker)	Tel: +44 (0)20 3207 7800
Toby Flaux / Detlir Elezi / Yasmina Benchekroun

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices .

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,600 employees. For more information, please see www.admedsol.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOREKLFLEVLFBBK